Crestline Management, LP Denali Therapeutics Inc. Transaction History
Crestline Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Crestline Management, LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Crestline Management, LP holds 4,760,732 shares of DNLI stock, worth $131 Million. This represents 8.67% of its overall portfolio holdings.
Number of Shares
4,760,732
Previous 5,210,732
8.64%
Holding current value
$131 Million
Previous $107 Million
3.39%
% of portfolio
8.67%
Previous 9.7%
Shares
19 transactions
Others Institutions Holding DNLI
# of Institutions
216Shares Held
115MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$378 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$362 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$311 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$270 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$196 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.69B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...